Occurrence and influencing factors of immune-related adverse events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors combined with chemotherapy
Objective:To investigate the incidence and risk factors of immune-related adverse events(irAE)in patients with non-small cell lung cancer(NSCLC)treated with immune checkpoint inhibitors(ICIs).Methods:98 patients with NSCLC treated with immune checkpoint inhibitors in our hospital from January 2019 to January 2022 were retrospectively analyzed.NSCLC patients were divided into irAE group(n=53)and non-NSCLC group(n=45)according to whether immune-related adverse reactions occurred after treatment.The clinical data of NSCLC patients in the two groups were analyzed and compared.Logistic regression was used to analyze the risk factors for immune-related adverse reactions in NSCLC patients.Results:The levels of absolute lymphocyte count(ALC),absolute eosinophil count,(AEC)and platelet-to-lymphocyte ratio(PLR)of NSCLC patients in irAE group were higher than those in non-CLC group,and the levels of neutrophil-to-lymphocyte ratio(NLR)were lower than those in non-CLC group(P<0.05).Logistic regression showed that ALC level was higher(OR=4.477,P=0.001)was an independent risk factor for irAE in NSCLC patients.Conclusion:High ALC level is an independent risk factor for irAE in NSCLC patients.
NETL
NSTL
万方数据
